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Abstract
The enzyme Pin1 is a peptidyl-prolyl cis-trans isomerase consisting structurally of two
domains, an N-terminal WW protein interaction domain and a C-terminal PPIase catalytic
domain. Both domains bind a phosphorylated serine/threonine-proline motif, however, a
precise mechanism regarding how binding to interactors is coordinated by both domains has
not yet been determined. Although multiple models exist to explain this process, it appears
that the interactions may be substrate-specific. With regards to a well–studied Pin1 interactor,
CDC25C, we hypothesize that binding occurs via the simultaneous model. This model
suggests that two binding sites, each having low affinity, may bind in concert producing a
higher affinity interaction. To investigate this we chose to employ a peptide-based approach,
using human CDC25C-derived peptides which contained the two identified Pin1 binding
sites in phosphorylated and non-phosphorylated combinations. These peptides were utilized
in two independent assays, surface plasmon resonance and fluorescence polarization, to
elucidate the domain- and phosphorylation-requirements of the Pin1-CDC25C interaction.
We showed that the interaction is phosphorylation-dependent, and is optimal when fulllength, wild-type Pin1 binds to a doubly-phosphorylated peptide. Collectively, our results
support our hypothesis that the Pin1-CDC25C interaction occurs via the simultaneous model,
and requires both domains.

Keywords
Pin1, peptidyl-prolyl isomerase, CDC25C, phosphorylated serine/threonine-proline motif,
models of binding, simultaneous model, peptide, surface plasmon resonance, fluorescence
polarization
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1.0

Introduction

Protein phosphorylation is a key mechanism in cellular signalling which allows for
precise spatial and temporal control over diverse and complex events. The
conformational changes that occur as a result of phosphorylation play a role in signal
transduction, for example, by driving protein-protein interactions or activating enzymatic
activity (1). Although this is true for phosphorylation of tyrosine, serine, or threonine
residues, the common phosphorylation motif of serine/threonine-proline allows for an
additional opportunity for post-phosphorylation regulation. This is due to the distinct cis
and trans conformations of proline residues, and although the intrinsic switch between
conformations is slow, it can be catalyzed by peptidyl-prolyl isomerases. These enzymes
play an important role in protein folding, however the discovery of a unique
phosphorylation-dependent peptidyl-prolyl isomerase, Pin1, added a new twist to
understanding the importance of proline-directed phosphorylation and resulting
conformational changes in cell signalling. Specifically, the catalytic isomerization
following phosphorylation will induce a conformational change which can subsequently
regulate protein function (2). This has since been shown to be true for a number of Pin1
interactors, proteins which have diverse functions in important cellular events including
mitosis, transcription, and DNA repair. This places Pin1 in an important role, as a key
regulator of many cellular processes, and emphasizes the significance of postphosphorylation regulatory mechanisms in signal transduction.
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1.1

Historical background

Pin1 is a phosphorylation-dependent peptidyl-prolyl isomerase that was first isolated by a
yeast two-hybrid screen designed to identify human proteins which interact with the
“Never in Mitosis” gene A (NIMA) (3). Sequence analysis revealed that human Pin1
exhibits approximately 45% sequence identity with the product of the ESS1 gene that
was previously identified as essential for growth in the budding yeast Saccharomyces
cerevisiae (4). It has subsequently been found that Pin1-like proteins are highly
conserved, found in both eukaryotes and prokaryotes (5). While it was initially implicated
as a regulator of mitosis, it is evident that Pin1 has roles in a number of biological
processes.
Pin1 is classified as a peptidyl-prolyl isomerase (PPIase) catalyzing the cis-trans
conversion of the peptide bond between a proline and the preceding amino acid (Figure
1). It is part of a large superfamily of PPIases, which is divided into three families: the
cyclophilins, the FK506 binding proteins (FKBPs), and the parvulins (6). One
distinguishing characteristic among the three families of PPIases is their substrate
specificities, particularly concerning the residue directly preceding the proline. Like all
members of the parvulin family, Pin1 has a preference for hydrophobic residues.
However, unique to Pin1 is its phosphorylation-dependence, requiring that the preceding
residue be a phosphorylated

serine or phosphorylated

threonine (7).

With

phosphorylation playing a pivotal role in cell signalling, one can infer that an isomerase
with phosphorylated residues in its specificity determinants would add an additional layer
of complexity to signalling pathways. This has been shown in multiple cellular processes

3

Figure 1 Peptidyl-prolyl isomerization.
Cis-trans isomerization of the peptide bond (arrow) preceding the proline. Xxx represents
any amino acid.
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where Pin1-catalyzed isomerisation regulates the conformation of key cellular proteins
(8).

1.2

Structural and enzymatic features of Pin1

High resolution structures of Pin1 determined by x-ray crystallography (9, 10) revealed
that it consists of two structural domains connected by a relatively short linker, which had
originally been predicted from its primary sequence (Figure 2). The N-terminal WW
domain is named for two conserved tryptophan residues and comprises residues 1-39. It
consists of a triple stranded anti-parallel β-sheet, with a hydrophobic patch in the surface
(11). Generally described as a protein-protein interaction domain, the WW domain of
Pin1 binds pSer/Thr-Pro motifs, and thus is thought to facilitate interactions between
Pin1 and its substrates (12). The 118 amino acid catalytic PPIase domain (residues 45163) is found on the C-terminal end of the protein, and consists of four antiparallel βsheets, and four α-helices. Within this domain are two relatively well described regions,
the proline binding pocket and the phosphate binding loop, which lie on opposite sides of
the active site. The hydrophobic proline binding pocket contains three highly conserved
residues, Leu122, Met130, and Phe134, which are thought to be responsible for holding
the proline in place during catalysis (9). The phosphate binding loop contains two
positively charged arginine residues at positions 68 and 69, as well as another positively
charged amino acid,

lysine at position 63, conferring upon Pin1 its preference for

phosphorylated residues preceding the proline (11). A short linker connects the WW and
PPIase domains, whose flexibility may contribute to the broad substrate specificity of
Pin1 (13). Interestingly, although both domains of Pin1 bind the pSer/Thr-Pro motif, it
appears that they may bind differently since the WW domain typically has a higher

6

Figure 2 Pin1 structure
A. Linear representation of Pin1. Phosphorylation sites are indicated.
B. and C. High resolution structure of Pin1 determined by NMR (PDB: 1NMV). B. The
WW domain is shown in blue, the linker region is yellow, and the PPIase domain is
shown in red. C. Key residues of the PPIase domain are highlighted. See text for more
details.

7

A.

B.

C.
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binding affinity for peptides than the PPIase domain (12). This has lead to the generation
of multiple models to explain how Pin1 binds to its substrates, which are reviewed in
section 1.8.
In spite of the evidence confirming the ability of Pin1 to catalyze cis-trans isomerisation,
there are still questions concerning its precise catalytic mechanism. On the basis of a
crystal structure of Pin1, Ranganathan et al. (9), initially proposed a mechanism that
involved the formation of a covalent enzyme-substrate intermediate with Cys113, His59,
and His157 being key residues involved in catalysis. Since then, however, additional
evidence has argued instead for a non-covalent mechanism. In this respect, Lippens et al.
(14) proposed that the role of Cys113 is to destabilize the peptide prolyl bond to allow for
its rotation. This hypothesis is supported by data from Behrsin et al. (15) showing that a
Cys113/Asp substitution did not abolish Pin1 function. Additionally, with regards to the
histidine residues, it has been shown that they do not directly participate in catalysis,
suggesting they instead act structurally to support the integrity of the active site (16).

1.3

Physiological regulation of Pin1

It appears that Pin1 is subject to regulation at a number of levels (8). For example, its
expression is upregulated in response to growth factors through E2F-mediated
transcription, an observation consistent with its role in the cell cycle (17, 18). Pin1 is also
regulated through post-translational modifications, including phosphorylation and
possibly oxidation. Phosphorylation on Ser16 and Ser65 has opposing effects: the former
prevents interactions with substrates (19, 20), while the latter reduces ubiquitylation, thus
increasing stability of Pin1 (21). Oxidation of Pin1 may have a relationship to pathologies
such as Alzheimer’s disease, rather than as a part of normal cell regulation (22, 23).

9

1.4

Cellular functions of Pin1

Pin1 is primarily localized in the nucleus (3), however, it can also be detected in the
cytoplasm (24-26). This pervasive distribution of Pin1 is consistent with its extensive list
of target proteins that are localized throughout the cell (27). As previously noted, Pin1
was first identified due to its interaction with NIMA, a protein kinase involved in mitotic
regulation. This relationship was the first of many which suggested that Pin1 plays an
integral role in regulation of the cell cycle and growth. Since then, Pin1 has been shown
to be involved in a variety of additional cellular processes by interacting with a numerous
substrates (28-39), emphasizing its diversity and importance (Table 1 provides a selection
of such processes and substrates). Loss of function mutations or deletions of Pin1 in yeast
and mammalian cells provides striking evidence for its role in the cell cycle, as these cells
undergo mitotic arrest and apoptosis (3, 4, 40-43). Furthermore, Pin1 has a lengthy list of
substrates which are known to be involved in the cell cycle, including a number of
mitotic regulatory proteins (e.g. CDC25 and WEE1) which are targets of proline-directed
protein kinases, such as CDKs and MAPKs (8). Pin1-catalyzed isomerisation of these
phosphorylated sites may be responsible for coordinating the activity of mitotic proteins,
thus allowing for progression through the cell cycle (8). Pin1 has also been shown to
coordinate duplication of centrosomes, DNA synthesis (44), and to assist in chromosome
condensation (45) further emphasizing its role in the cell cycle.
Similar to its actions in the cell cycle, Pin1 has been shown to interact with proteins
involved in cell signalling events and pathways involving proline-directed protein
kinases. One such example is the MAPK pathway, where, following proline-directed
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Table 1 Selected Pin1 substrates and consequences of interaction.

SUBSTRATE

Cell Cycle
Regulation

Apoptosis

CONSEQUENCE OF PIN1
INTERACTION

CDC25

Dephosphorylation

WEE1

Inhibition of activity

Cyclin D1

Stabilization

p53

Stabilization

Tau

Dephosphorylation

APP

APP processing

Neuro-degeneration
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phosphorylation by MAPK, the proteins c-Jun and c-Fos are acted upon by Pin1 (18, 24,
26, 46, 47).
Briefly adding to the growing list of functions, Pin1 has also been shown to regulate
expression of some genes through regulation of their transcription factors (24, 25, 33-35,
47-50), to assist in the maintenance of telomeres through interactions with TRF1 (51), to
facilitate DNA repair through interactions with p53 (52), and finally, to support breast
development (53).
Additionally, Pin1 has been shown to have specific roles in the immune and nervous
systems. These additional functions provide links to the implication of Pin1 in various
pathogenic conditions, which will be discussed in the following section. In short
however, it has been shown that Pin1 is important for regulating transcription of
cytokines in T cells, as well as for survival of eosinophils (54). The importance of Pin1 in
the brain is evident in Pin1 knockout mice, which have progressive and age-related
neurodegeneration (55). This is directly related to the ability of Pin1 to promote normal
neuronal cell functioning and survival through the interaction with proteins such as Tau
and amyloid precursor protein (APP) (30, 36-39).

1.5

Pin1 in pathogenesis

Considering the diversity of its roles and importance as a key regulator of many cellular
and biological processes, it is not unexpected that Pin1 appears to be involved in various
pathological conditions, including cancer, Alzheimer’s disease, and asthma. In this
respect, Pin1 has been implicated in a variety of cancers, including breast, lung, colon
and prostate cancer (8). This is not surprising given its role as a regulator of the cell
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cycle. However, the precise role Pin1 plays in cancer is controversial, as levels of Pin1
have been shown to be either positively or negatively related to cancer (56). One of the
better understood pathways in which overexpression of Pin1 appears to participate in
cancer involves cyclin D1. Not only can Pin1 increase expression of cyclin D1 (24, 25,
48), Pin1 can also directly bind and stabilize cyclin D1 to enhance cyclin D1/CDK
activity (26). Conversely, loss of Pin1 can suppress transformation by Neu or Ras (18).
Additionally, Pin1 has been shown to stabilize p53, an important tumour suppressor
which promotes apoptosis in response to genotoxic stresses (33-35).
With regards to Alzheimer’s disease, the precise role of Pin1 in pathogenesis remains
uncertain, although evidence suggests that various mechanisms in Alzheimer’s disease
downregulate and/or inactivate Pin1 (for example, through oxidation (22)), suggesting it
has a neuroprotective role (57). The loss of Pin1 function has impacts on two proteins,
namely APP and Tau, both found in senile plaques and neurofibrillary tangles. A current
model suggests that without Pin1, the pThr668-Pro motif of APP remains in the cis form
and accumulates in plaques (38). Similarly, the Tau pThr231-Pro motif is also found
mostly in the cis form, leading to its hyperphosphorylation and subsequent accumulation
(30, 55).
The association between Pin1 and asthma can be traced back to the role Pin1 plays in
immune cell function. By regulating the release of cytokines from eosinophils, and
participating in the apoptotic decision of both T-cells and eosinophils, activated Pin1
modulates the allergic inflammatory response in the lungs associated with asthma (58).
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1.6

Emergence of Pin1 as a candidate for molecular-targeted
therapy

The prevalence of Pin1 in various human diseases, cancer in particular, makes it an
obvious candidate for therapies. Additionally, the fact that other PPIase proteins,
specifically cyclophilin and FKBP, have been shown to be good therapeutic targets lends
support to attempts to achieve the same success with Pin1. The first general inhibitor of
parvulins was juglone, and although it has the ability to irreversibly inhibit Pin1, its use
as an anticancer therapy is limited by its non-specificity (59). More recently, work has
been focused on structure-based design of Pin1 inhibitors. Features that have been
targeted by these rationally-designed Pin1 inhibitors include its hydrophobic binding
pocket, the phosphate binding loop (60), or Cys113 within its active site (61). Thus far,
these Pin1 inhibitors have had varying degrees of specificity, as well as issues with
potency, degradation, and cell permeability. In addition to these inhibitors, there have
also been efforts to isolate inhibitors in the form of cyclic peptides which are less likely
to be subject to proteolysis and may bind Pin1 with a higher affinity due to their reduced
flexibility (62, 63). Although some inhibitors are able to inhibit Pin1 at nanomolar
concentrations, their usage currently appears to be more appropriate for further
investigations regarding the cellular functions of Pin1, rather than as therapeutic agents.
However, this does not preclude the notion of using them as models to guide the design
of novel, potentially therapeutic inhibitors of Pin1.

1.7

Pin1 and CDC25C

The progression of determining functions of Pin1, its pathogenic implications, and
subsequently investigating the potential for targeted therapy began with the identification

14

of Pin1 interacting proteins. In 1998 human CDC25C (and its Xenopus homologue) was
among the first proteins to be identified as a Pin1 interactor (28, 29) and since then
details of this interaction and its implications have been further elucidated.
CDC25C is a dual-specificity phosphatase, often referred to as a mitotic trigger due to its
importance in the initiation of mitosis (64). It is not surprising therefore, that CDC25C is
subject to multiple post-translational modifications which tightly regulate its function.
One such modification is hyperphosphorylation, which results in activation of CDC25C
(65), and the resultant rapid initiation of mitosis (66). Of equal importance is the
subsequent activity of phosphatases, which act to counter the activating effects of
phosphorylation. However, the resulting dephosphorylation is dependent upon Pin1
binding to pT48 and pT67 (12, 30). This result provided evidence for multi-step
regulation in mitosis (phosphorylation of specific Ser-Thr/Pro motifs followed by Pin1catalyzed isomerization) and emphasized the role of Pin1 as a mitotic regulator capable
of synchronizing events. CDC25C (both human and Xenopus) and peptides derived from
it have since been used to further investigate the interaction with Pin1, as well as the
structure and function of both the WW and PPIase domains with respect to their
interaction with CDC25C (12, 19, 67-70). This has led to the discovery that the
interaction between Pin1 and CDC25C requires full-length Pin1, as individual WW and
PPIase domains failed to interact with the phosphatase (71). Interestingly, this is not the
case for all interactors of Pin1 (71), and suggests that interactions are substrate-specific.
This adds yet another twist to the role Pin1 plays in post-phosphorylation mechanisms.
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1.8

Models of binding

As an enzyme with binding capabilities in both domains, one of the key outstanding
questions with regards to Pin1 is the mechanism with which it binds its interactors. To
this end, multiple models to explain the binding mechanism have been proposed, as
summarized in Figure 3. The first of four models to be reviewed here is the catalysis-first
binding model (Figure 3A), suggested by Wintjens et al. (68). Given that the WW
domain of Pin1 has been shown to bind targets in the trans conformation (10, 19, 68),
this model suggests that the PPIase domain binds to a pSer/Thr-Pro site in the cis
conformation, and subsequently catalyses the cis-trans isomerization, thus creating a
WW-domain binding site. The multimeric model (Figure 3B) suggests that Pin1 exists
within a multi-protein complex, bound by its WW domain to another protein. This would
then put the PPIase domain in proximity to the Pin1 target, and thus allow for
isomerization (72). The third model is the sequential model (Figure 3C), put forward by
Zhou et al. (11). This model suggests that the WW domain of Pin1 binds pSer/Thr-Pro
targets first. The PPIase domain then either binds to the same target (once the WW
domain has released it), or binds to an adjacent target to perform isomerization. This
model relies on data showing differences in affinity for target sequences, with the WW
domain having higher affinity than the PPIase domain (12). Additionally, in cases where
the PPIase domain may bind a second pSer/Thr-Pro motif, this model is supported by
Pin1 interactors which have multiple (identified) Pin1 binding sites, for example,
CDC25C (12, 30), protein kinase CK2 (73), RNA binding protein p54nrb (74), and
microtubule binding protein Tau (30, 36, 37). Recently, a fourth model has been
proposed by Innes et al. (71) (Figure 3D). This simultaneous model is similar in one
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Figure 3 Schematic representation of models of Pin1 binding
A. The catalysis-first model suggests that the PPIase domain of Pin1 binds to a pS-T-P
site in the cis conformation. Following subsequent catalysis by the PPIase domain a WWdomain binding site is generated.
B. The multimeric model suggests that Pin1 exists within a multi-protein complex, bound
by its WW domain to another protein. The PPIase domain would theoretically be in
proximity to the Pin1 target, and thus, catalyze isomerization.
C. The sequential model suggests that the WW domain of Pin1 binds pS/T-P targets first.
The PPIase domain will then either bind to the same target (once the WW domain has
released it), or bind to an adjacent target to perform isomerization.
D. The simultaneous model suggests that Pin1 binds a multi-phosphorylated target with
both the WW domain and the PPIase domain, as each individual site may have low
affinity. Binding by both domains at the same time produces a higher affinity interaction.
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A.

B.

C.

D.
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aspect to the sequential model in that it suggests that Pin1 binds a multi-phosphorylated
target with both the WW domain and the PPIase domain. It differs however, in how that
interaction begins. While the sequential model suggests that a high-affinity WW domain
site binds first, the simultaneous model suggests that some sites may have low affinity for
the WW domain, and therefore require binding by both domains at the same time in order
to produce a higher affinity interaction. Given the data to support each suggested model,
it would appear that Pin1 may have more than one way to interact with its various targets.

1.9

Rational, objective, and hypothesis

Since its discovery in 1996, much has been learned regarding the structure, function, and
regulation of Pin1. In comparison to other PPIases, one particularly intriguing feature of
Pin1 is its phosphorylation dependence which enables Pin1 to introduce an additional
level of control in pathways involving proline-directed protein kinases such as CDKs that
are central drivers of cell cycle progression. While Pin1 was initially implicated as a key
regulator of mitosis, it has subsequently been shown to be important in a diverse array of
cellular processes. In concert with its participation in a broad spectrum of biological
events, it is noteworthy that Pin1 has been implicated in a variety of diseases including
cancer, neurological disorders such as Alzheimer’s disease and asthma. Pin1 has thus
emerged as a potential candidate for molecular-targeted therapy. Consequently, it can be
anticipated that ongoing efforts to understand its regulation and functions and to elucidate
its precise catalytic mechanism will foster efforts to develop new approaches that will
harness its promise as a therapeutic target. Furthermore, the design of inhibitors of Pin1
will likely be aided by knowledge of the ways in which Pin1 interacts with its targets.
However, the dual-domain structure of Pin1 complicates this process, and it appears that
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the interactions may vary, depending on the substrate. This represents a rather large gap
in the knowledge regarding Pin1, and as a result, the goal of this work was to further
elucidate the mechanism through which Pin1 interacts with a key mitotic initiator,
CDC25C.
The interaction between Pin1 and CDC25C provided evidence for the role of Pin1 as
regulator of mitosis, using a post-phosphorylation mechanism. Specifically, CDC25C is
dephosphorylated, and thus inhibited, in response to Pin1 catalyzed isomerization, thus
preventing entry into mitosis. Since the interaction between these two proteins requires
the presence of full-length Pin1, I hypothesized that this requirement is a result of Pin1
binding using both domains simultaneously. To address this hypothesis, I chose to
perform a thorough investigation of the domain and phosphorylation requirements that
facilitate the interaction between Pin1 and CDC25C. To this end, I employed a peptidebased strategy, using two independent yet complementary assays to promote precision
and accuracy.
The first assay employs fluorescence polarization, enabling for the detection of the
interaction between an analyte and ligand, both of which are in solution. Specifically,
following excitation the fluorescently labelled ligand will emit light in all planes as a
result of its mobility in solution, however, binding of the ligand to an analyte will
decrease its mobility thereby increasing the amount of emitted light which is polarized
(75). Polarization of emitted light is therefore an indicator of the interaction between the
ligand and analyte, and can be analyzed quantitatively and qualitatively to study their
affinity (75).
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The second peptide-based assay utilizes the phenomena of surface plasmon resonance
(SPR) to detect the binding between a ligand and an analyte. Specifically, interactions
between a free-flowing analyte and an immobilized ligand can be detected as a result of
changes in mass on the immobilization surface. As the mass changes, so to will the angle
at which a reduced amount of polarized light is reflected (due to changes in SPR), which
is reported in the form of response units (RU) (76). Monitoring of the RU over the course
of the interaction produces a sensorgram which can subsequently be analyzed, both
qualitatively and quantitatively, to study the affinity between the analyte and ligand (76).
To summarize, although the above methodologies have been used with singly
phosphorylated peptides to identify and characterize interaction sites, a comprehensive
report which combines an investigation of the domain requirements with the impact of
multiple phosphorylation sites with regards to human CDC25C has not been published.
As a result, the present approach is unique in its use of a multiphosphorylated human
CDC25C-derived peptide.
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2.0
2.1

Materials and Methods

GST fusion protein purification

GST fusion proteins were expressed from pGEX constructs (courtesy of Melanie Bailey,
Litchfield lab, University of Western Ontario (77)) transformed into E. coli strain BL21.
Individual colonies were grown in 2xYT broth with 100 µg/mL ampicillin (Roche) at 37
°C until an optical density of 0.6 at 600 nm had been reached. Protein expression was
then induced with 0.6 mM IPTG (Roche) for 2 hours. Bacteria were pelleted by
centrifugation for 15 min at 4420 xg, resuspended in cold PBS containing protease
inhibitors (1 mM PMSF (Sigma), 10 µg/mL pepstatin A (Sigma) and 10 µg/mL leupeptin
(Sigma)) and then lysed by sonicating six times 1 min each on ice. Triton X-100 (Sigma)
was added to 1% and the mixture was rotated for 15 min at 4°C.
Cell debris was pelleted by centrifugation for 20 min at 23 300 xg and the supernatant
was incubated with glutathione cross-linked agarose beads (Sigma) for 1 hour at 4 °C
with rotation. After washing beads with 2 column volumes of cold PBS, protein was
eluted in five steps with 10 mM reduced glutathione (Sigma) in PBS, followed by 3 steps
with 30 mM reduced glutathione (Sigma) in PBS. Aliquots of washes and eluates were
analysed by 10-15% SDS-PAGE gels in SDS-PAGE buffer (192 mM glycine (Bioshop),
25 mM Tris-base (Bioshop), 0.1% SDS (Bioshop)) at a constant voltage of 180 V for 1
hour. New England Biolabs broad range prestained molecular marker was used for
reference. Protein purity was assessed by staining with Coomassie Blue (Bio-Rad).
Fractions containing pure protein were then dialysed at 4 °C for 16-18 hours into PBS
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containing 20% glycerol (Caledon) for storage at -80 °C. Protein concentrations were
determined using the Bradford Protein Assay (Bio-Rad).

2.2

Cleavage of GST fusion proteins

Proteins used for isomerase assays, and both Biacore and Fluoresence Polarization (FP)
experiments were expressed as GST fusions and purified as above, but without dialysis
into storage buffer. Instead, TEV protease was added to proteins in a mass ratio of 1:100
for 4 hours at room temperature with 5 mM DTT and 0.5 M NaCl. Proteins were dialysed
at 4 °C for 16-18 hours into Buffer A (150 mM NaCl, 50 mM Na2HPO4, 5 mM NaN3, pH
7.8) followed by loading onto a 120 mL HiPrep 16/60 Sephacryl S-100 High Resolution
filtration column (GE Healthcare). Proteins were eluted with Buffer A in ninety-six 1.5
mL fractions. As before, aliquots of fractions were analysed by 10-15% SDS-PAGE gels
and staining with Coomassie Blue to assess purity and those containing pure protein were
pooled and dialysed at 4 °C for 16-18 hours into HBS-E (10 mM HEPES pH 7.4, 150
mM NaCl, 3.4 mM EDTA). Protein concentrations were determined using the Bradford
Protein Assay (Bio-Rad).

2.3

Cell culture and transfection

HeLa cells were maintained at 37 °C and 5% CO2 in DMEM (Invitrogen) supplemented
with 10% FBS (Thermo Scientific) and 1% penicillin/streptomycin (Invitrogen).
Transfections were performed on cells at ~50% confluence on 10 cm tissue culture plates
following the addition of 5 mL of fresh media. All transfected plasmid constructs
(courtesy of Kathryn Volkening, Strong Lab, University of Western Ontario) were
purified by cesium chloride purification methods. For transfections, 60 µL of 1 mg/mL
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PEI (Polysciences Inc.) was added to 440 µL of 150 mM filter sterilized NaCl and 10 µg
plasmid DNA. Following vortexing for 10 s, complexes were allowed to form for 10
minutes, before addition to cells. After 16-18 hours, transfected cells were washed with
PBS (Invitrogen), fresh media was added, and cells were allowed to grow for an
additional 16-18 hours. To arrest cells in mitosis, cells at ~75% confluency were treated
with 0.25 µg/mL nocodazole (Sigma) for 18 hours before harvest.

2.4

Lysate preparation

Cells were harvested by shake off and pelleted at 300 xg for 3 min at 4 °C. Cell pellets
were washed and re-pelleted twice, with cold PBS containing protease and phosphatase
inhibitors (1 mM PMSF (Sigma), 10 µg/mL pepstatin A, 10 µg/mL leupeptin, 1 µM
microcystin-LR (Cayman Chemical), 1 µM oakadaic acid (Bioshop), and 1 mM sodium
orthovanadate (Aldrich Chemical)). Cells were resuspended in cold lysis buffer (50 mM
Tris-HCl, pH 8, 200 mM NaCl, 10% glycerol, 1% Triton X-100) with added protease
inhibitors as listed above. Cells were allowed to lyse at 4 °C for 2-3 hours with rotation.
Cell debris was then spun down by centrifugation first at 24 100 xg for 15 min and then
at again for 30 min. Protein concentration was determined using the BCA protein assay
(Thermo Scientific). Cell lysates were either used immediately in pull-downs, or frozen
in aliquots at -80 °C.

2.5

GST pull-downs

100 µg of GST fusion protein was incubated with 20 µL of a 1:1 slurry of glutathione
cross-linked agarose beads (Sigma) to PBS for 30 min at 4 °C with rotation. The beads
were then washed 3 times with cold PBS, and 1 mg of cell extract (prepared as described
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in section 2.4) was added and allowed to incubate for 1 hour at 4 °C with rotation. The
beads were then washed 3 times with cold PBS. Following removal of the last wash,
proteins were eluted into 50 µL of 2X Laemmli sample buffer (4% SDS, 20% glycerol,
120 mM Tris-HCl, pH 6.8, 10% β-mercaptoethanol) by boiling at 100 °C for 3 min.

2.6

SDS-PAGE and western blotting of pull-downs

All pull-downs were run on 10% SDS-PAGE gels in SDS-PAGE buffer (192 mM
glycine, 25 mM Tris-base, 0.1% SDS) at a constant voltage of 180 V for 1 hour. New
England Biolabs broad range prestained molecular marker was used for reference.
Proteins were then transferred to polyvinyl difluoride membrane (Millipore) over 1 hour
at 15 V, using a semi-dry transfer unit (Biorad) in blotting buffer (20% methanol, 10 mM
Tris-base, 767 mM glycine). Membranes were blocked for 1 hour at room temperature in
Odyssey Li-Cor blocking buffer (Li-Cor Biosciences) as per manufacturers’
specifications, followed by three 5 min washes with TBS-T (200 mM Tris-HCl, pH 7.5,
500 mM NaCl, 0.1% Tween 20). All antibody dilutions were done in TBS-T containing
1% bovine serum albumin (Sigma). Primary antibodies used are as follows: MPM-2 (2
µg/mL; Millipore), Cdc25C (C20) (1/100; Santa Cruz), Tau (T14/T16) (1 µg/mL;
Invitrogen), EGFP (0.2 µg.mL, Invitrogen), and NonO (1/2000, Abcam). After
incubation with primary antibodies at 4 °C for 16-18 hours, membranes were washed
three times with TBS-T, for 5 min each time. Membranes were then incubated with 1:10
000 dilutions of either GAM or GAR secondary antibodies for 1 hour at room
temperature. After three 5 min washes with TBS-T, and one 5min wash with TBS,
membranes were visualized on a Li-Cor near-infrared fluorescent scanner and
quantifications were performed using Odyssey software (Version 3.0).
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2.7

CDC25C peptides

Human CDC25C-derived peptides were synthesized by EZBiolab (USA). Peptides were
prepared to 95-96% purity, as determined by HPLC (by EZBiolab). Peptide sequences
were as follows: PDVPRpTPVGKFLGDSANLSISGGpTPKRSLDW-beta-A-beta-Abeta-A-C,

PDVPRpTPVGKFLGDSANLSISGGTPKRSLDW-beta-A-beta-A-beta-A-C,

PDVPRTPVGKFLGDSANLSISGGpTPKRSLDW-beta-A-beta-A-beta-A-C

(herein

referred to as 2xP, 1xP #1, and 1xP #2 respectively). Dephosphorylated peptide (herein
referred to as De-P) was obtained following phosphatase treatment of phosphorylated
peptide. Phosphorylated peptide at 100 µM in HBS (10 mM HEPES, 10 mM NaCl, pH
7.0) was incubated with 400 units of λ-protein phosphatase (New England Biolabs), with
the addition of λ-phosphatase buffer (New England Biolabs) and 1 mM MnCl2. The
reaction was allowed to proceed for 60 min at 30 °C, followed by dialysis of peptide into
HBS (10 mM HEPES, 10 mM NaCl, pH 7.0). Dephosphorylation was confirmed with
MALDI Mass Spectrometry (within the MALDI Mass Spectrometry Facility that is part
of the London Regional Proteomics Centre).

2.8

Biacore surface plasmon resonance binding measurements

All measurements were performed on a BIAcore X instrument (GE Health Sciences)
equipped with CM5 sensor chips maintained at 25 °C. All buffer solutions were filtered
and de-gassed prior to use. Peptide immobilization was performed using the ligand thiol
method, described as follows. A continuous buffer flow consisting of HBS-E (10 mM
HEPES pH 7.4, 150 mM NaCl, 3.4 mM EDTA) was maintained at 5 µL/min. The
carboxylated dextran matrix of one flow cell in each CM5 sensor chip (GE Healthcare)
was activated by a 10 µL injection of a solution containing equal volumes of 100 mM N-
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hydroxysuccinimide and 400 mM 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide,
followed by a 20 µL injection of 80 mM 2-(2-pyridinyldithio)ethaneamine in 0.1 M
sodium borate pH 8.5. 35 µL of peptide to be immobilized at 20-30 µM in 10 mM
sodium borate, pH 6.0 was then injected, followed by a 20 µL injection of a solution of
0.1 M sodium acetate, pH 4.0, containing 50 mM cysteine and 1 M NaCl. Immobilization
was indicated by a change in baseline of 500-900 RU. The second flow cell of each chip
was treated identically, without the injection of peptide solution.
Protein samples (10 µL of 5-20 µM) were injected over the chip surface at a flow rate of
10 µL/min, and the peptide-protein complex was allowed to dissociate for 1-2 min.
Complete dissociation of protein was achieved following a 5 µL injection of 10 mM
NaOH. Analysis was performed using Biaevaluation Software 4.1.1 (GE Health
Sciences), following subtraction of background as measured in the non-immobilized flow
cell.
Whenever possible, assays with different peptides were performed at the same time.
Otherwise, binding ability (or lack thereof) was confirmed with single injections of
protein on the sensor chips immobilized with doubly- or de-phosphorylated peptide.

2.9
All

Fluorescence polarization measurements
peptides

were

fluorescently

labelled

with

fluorescein-5-maleimide

(Life

Technologies). Peptides were dissolved at 75-120 µM in HBS (10 mM HEPES, 10 mM
NaCl, pH 7.0) and DTT was added in 10-fold molar excess. Following overnight dialysis
to remove excess DTT, fluorescein-5-maleimide (10 mM in DMSO) was added in 10-20fold molar excess. The reaction was incubated overnight at 4°C, and excess fluorescent
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reagent was consumed with 10-fold molar excess β-mercaptoethanol. Peptides were
dialyzed into HBS as before, and labelling was confirmed with MALDI. At all times
during and following labelling, peptides were stored in the dark.
All fluorescence polarization assays were read using an Envision 2103 multiplate reader
(PerkinElmer). Optimal dilutions for each peptide were determined and employed in all
future experiments. Individual reactions were carried out in duplicate, in a total volume
of 35 µL per well in a 384-well black plate (Corning). A serial dilution of the protein
sample was prepared, and 30 µL was added to each well, followed by 5 µL of peptide.
Following 1 min incubation with agitation (500 rpm) at room temperature, the plate was
spun at 100 xg for 1 min, and fluorescence polarization was read. Analysis was
performed using Microsoft Excel (Microsoft) by subtracting reference (buffer)
polarization, as well as polarization associated with non-specific interactions between
protein and the fluorescein-5-maleimide tag.

2.10 In vitro isomerase assays
Assays were performed at 0 °C in a Cary-100 spectrophotometer. The Suc-AEPF-pNA
substrate (Bachem) was dissolved trifluoroethanol containing 0.3 M LiCl, and the
chymotrypsin (Type II; Sigma-Aldrich) was dissolved to a concentration of 50 mg/mL in
1 mM HCl. To assay isomerase activity of Pin1 constructs, substrate at the appropriate
concentration was added to 2 mL of assay buffer (100 mM NaCl, 50 mM HEPES, 5 mM
NaN3, pH 7.4) and allowed to incubate for approximately 30 s. Chymotrypsin (50 µL)
was then added and following consumption of peptide containing trans-proline, the rate
of chemical isomerization was measured for approximately 30 s. Pin1 was then added to
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the system, and the rate of Pin1-catalyzed prolyl isomerization together with chemical
isomerization was measured. Absorbance measurements were made at 405 nm, 430 nm,
or 445 nm, depending on the substrate concentration, to ensure that optical density did
not exceed 2.0 absorbance units. Rates of reaction for 5 different substrate concentrations
were recorded, corrected for the rate of chemical isomerisation and enzyme
concentration, and plotted against substrate concentration to determine the kcat/KM.

2.11 Differential scanning calorimetry
Differential scanning calorimetry was performed on a MicroCal VP-DSC Differential
Scanning Calorimeter (GE Healthcare). All solutions were degassed prior to DSC runs.
The equipment was first calibrated using 10-20 scans of buffer only, followed by a single
scan with sample. Scans were performed by heating from 10 °C -110 °C at 1 °C/min,
with pressures of between 23.5-25 psi. Analysis was performed using Origin software
(Version 7.0) provided by the manufacturer. Reference (buffer) runs were subtracted, and
data was normalized to concentration of sample in order to determine the transition
temperature. For samples to be used in additional experiments, sample was removed
immediately after the transition temperature was reached to prevent precipitation.
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3.0
3.1

Results

Protein purification

As a first step towards testing the determinants of the interaction between Pin1 and
CDC25C, recombinant Pin1 proteins were purified. GST fusion proteins were selected
for ease of purification, as well as to allow for GST-pullown experiments. Additionally,
GST fusion constructs had previously been designed (71, 77) to incorporate a TEV
cleavage site between the GST tag and the protein. This allowed for the generation of tagfree proteins for additional assays where tags may have confounded results. Both GST
and all GST-Pin1 fusion proteins (Figure 4) were produced in bacteria and purified using
glutathione agarose beads. The expressed proteins displayed the expected molecular
weights (Figure 5). For proteins used in isomerase assays, and both SPR and fluorescence
polarization experiments, TEV cleavage followed by gel filtration also produced proteins
of expected molecular weights (Figure 6). Proteins were purified in relatively high
concentrations (2-15 mg/ml).

3.2

Pin1 interacts with CDC25C

The interaction between Pin1 and CDC25C has been show to require full-length Pin1,
implying that binding occurs via a simultaneous model (71). As a first step towards
testing this hypothesis, we sought to confirm the interaction with GST pulldowns using
mitotic HeLa cell lysates. Proteins that bound to GST or GST-Pin1 fusion proteins were
examined by immunoblotting with CDC25C antibody (Figure 7). Multiple bands
representing CDC25C were readily detected in the mitotic cell extract. Full length Pin1
showed interaction with CDC25C, while both the R68/69A mutant Pin1 and the Pin1
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Figure 4. Illustration of GST-Pin1 fusion constructs used in this study.
Several GST-Pin1 constructs were used. GST-Pin1 is a fusion protein consisting of the
full length Pin1 (residues 1 to 163) with the GST protein attached to the N-terminal.
GST-Pin1 Y23A is full length Pin1 with a single substitution within the WW domain that
decreases interactions between Pin1 and its interactors. GST-Pin1 R68/69A is full length
GST-Pin1 with two point mutations that dramatically decrease the isomerisation activity
of Pin1. Truncated GST-Pin1 constructs were also used, each consisting of only one Pin1
domain, the WW domain (residues 1 to 40) or the isomerase (PPIase) domain (residues
48 to 163).
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Figure 5. GST and GST-fusion protein purification.
GST and GST fusion proteins were isolated from bacterial lysate following induction
with IPTG by affinity chromatography using glutathione agarose beads. Samples were
run on 10-15% SDS-PAGE gel and proteins visualized with Coomassie Blue. The
expected molecular weight for each protein in indicated as follows: GST 26kDa, GSTPin1 (including full length mutants) 44kDa, GST-Pin1 WW Domain 32kDa, GST-Pin1
PPIase Domain 39kDa. Arrows indicate bands containing protein construct. Lane inputs
are as follows: M-marker, F-flowthrough, W-wash(es), E-elution(s), +/- IPTG-pre/post
induction with IPTG.
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Figure 6. Untagged protein purification.
GST fusion proteins were isolated as previously described. Following TEV cleavage,
proteins were separated by gel filtration chromatography using a HiPrep 16/60 Sephacryl
S-100 High Resolution filtration column. Samples of fractions were run on 10-15% SDSPAGE gel and proteins visualized with Coomassie Blue. The expected molecular weight
for each protein in indicated as follows: Pin1 (including full length mutants) 18kDa, Pin1
WW Domain 6kDa, Pin1 PPIase Domain 13kDa. Arrows indicate bands containing
protein construct. Lane inputs are as follows: M-marker.
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Figure 7. GST-Pulldown confirms the interaction between Pin1 and CDC25C.
Mitotic HeLa cell lysates were used in GST and GST-Pin1 fusion protein binding assays.
Proteins bound to the GST and GST-Pin1 beads were run on 10% SDS-PAGE gel and
transferred to membranes. Input represents 2 % of mitotic HeLa cell lysate used. Blots
were probed with antibody for CDC25C.

37

kDa

M

GST

GST-Pin1

GST-Pin1
R68/69A

GST-Pin1
WW-domain

GST-Pin1

GST

GST-Pin1
R68/69A

GST-Pin1
WW-domain

Input

175
CDC25C
80

38

WW domain, did not. No CDC25C was detected in the GST binding assay indicating that
the Pin1 portion of the GST-Pin1 fusion proteins is that which is responsible for
interactions with CDC25C. Overall, these results confirmed that full length Pin1 interacts
with CDC25C, in a manner that appears to require the presence of both, intact domains.

3.3 The interaction between Pin1 and CDC25C peptide is
phosphorylation-dependent
Pin1 is known to interact preferentially with phosphorylated serine or phosphorylated
threonine residues that precede a proline residue (7). As a fairly well characterized
interactor of Pin1, CDC25C has two described Pin1 binding sites, T48 and T67 (12, 30)
(Figure 8A). To determine the importance of phosphorylation of these binding sites with
regards to Pin1 binding we employed two independent assays, using SPR and
fluorescence polarization, to test the interaction between Pin1 and peptides derived from
human CDC25C.
Peptides were synthesized to contain both phosphorylation sites, as well as upstream and
downstream residues (Figure 8B). Three beta-alanine residues were added to the Cterminal end of the peptide to act as a spacer between the residues of the sequence and
the surface of the chip used for SPR. Also, since peptide immobilization on chip surfaces
was performed using a ligand thiol method (Figure 9A), a cysteine residue was added to
the C-terminal. To ensure peptide immobilization was uniform, C71 was substituted with
a serine residue to maintain similar amino acid size and structure.
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Figure 8. Human CDC25C-derived peptides used in this study.

A. Human CDC25 protein sequence is shown, with Pin1 binding sites, T48 and T67
identified in bold (UniProt P30307.2). Amino acid numbers are indicated on the left.

B. Peptide sequences and associated shorthand names of peptides used in this study.
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B.

Peptide Sequence

Peptide Shorthand
Name

PDVPRpTPVGKFLGDSANLSILSGGpTPKRSLDW-AAAC

2xP

PDVPRpTPVGKFLGDSANLSILSGGTPKRSLDW-AAAC

1xP #1

PDVPRTPVGKFLGDSANLSILSGGpTPKRSLDW-AAAC

1xP #2

PDVPRTPVGKFLGDSANLSILSGGTPKRSLDW-AAAC

De-P
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CDC25C derived peptides containing either both phosphorylated residues, or no
phosphorylated residues, were immobilized onto one flow cell of individual CM5 chips
following the ligand thiol method (Figure 9A). A typical sensorgram illustrating
immobilization is shown in Figure 9B. The immobilization of 2xP, as well as other
peptides, followed this typical pattern as shown in Figure 9C. Immobilization was
indicated by a change in baseline response, from that following the injection of PDEA, to
the final response after injection of cysteine/NaCl. Differences in response units in this
study ranged from 500 RU to 900 RU.
Following immobilization, Pin1 was injected over the surfaces of both flow cells and
dissociation was monitored. A typical sensorgram illustrating analyte-ligand binding is
shown in Figure 10A, while the results of the Pin1-2xP interaction are shown in Figure
10B. Pin1 showed a direct interaction with 2xP, having distinct association, equilibrium,
and dissociation phases. In contrast, the steady baseline level in Figure 10C indicates that
there is no detectable binding of De-P by Pin1. The binding results are specific to
interactions between Pin1 and peptide, as non-specific interactions between Pin1 and the
carboxylated dextran matrix of the chip have been accounted for in the non-immobilized
flow cell, and subsequently subtracted. The spikes seen in the Pin1-De-P sensorgram are
a result of the small time difference between analyte injection over each flow cell.
The phosphorylation-dependence of Pin1 was also evaluated by fluorescence polarization
assays. For these experiments, Pin1 was incubated independently with fluorescein-5maleimide-labelled CDC25C-derived peptides, and fluorescence polarization was
measured. Background fluorescence polarization as a result of labelled peptide in buffer
alone was subtracted. The results for Pin1 binding to 2xP mimicked a classic binding
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Figure 9. Peptide immobilization on sensor chip CM5.

A. Schematic illustrating immobilization chemistry via ligand thiol method. For
simplicity, the peptide sequence is represented by ‘Peptide’ except for the last section,
where 2xP sequence is used for representative purposes only.

B. Schematic sensorgram showing typical immobilization sequence associated with the
ligand thiol method. Injections of EDC/NHS, PDEA, ligand, and cysteine/NaCl are
marked. Immobilization is confirmed by the change in baseline response units, pre- and
post-injections.

C. Representative sensorgram of SPR analyses for peptide immobilization. The curve
shows the specific signal obtained during immobilization of 1xP #1 peptide and is
representative of other peptide immobilizations.
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Figure 10. SPR results indicate that binding of Pin1 to CDC25C-derived peptide is
phosphorylation-dependent.

A. Schematic sensorgram, showing association, equilibrium and dissociation phases
typical of the interaction between an analyte and its immobilized ligand. Association of
analyte with ligand occurs during sample injection. Equilibrium, or steady state, is
reached as analyte is continually supplied and removed by sample flow. Return to buffer
flow results in dissociation of analyte from surface.

B. and C. Sensorgrams of SPR analyses of the interaction between Pin1 and 2xP peptide
(B.), and Pin1 and De-P peptide (C.). Indicated concentrations of Pin1 were injected
through both flow cells for 1 minute. The curves show the specific signal obtained after
subtraction of background.
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curve, with a horizontal asymptote corresponding to 100% saturation (Figure 11A). This
is contrary to the results seen with De-P, where no measureable binding was detected
(Figure 11A). To determine if the interaction between Pin1 and the labelled peptide was
specific, additional assays were run using Pin1 and fluorescein-5-maleimide only. The
results (Figure 11B) with low polarization values were indicative of non-specific
interactions. These values were subtracted from all fluorescence polarization assays to
account for non-specific interactions between Pin1 and the fluorescein tag.
Results from the SPR and fluorescence polarization assays were used to estimate the
equilibrium dissociation constant between Pin1 and 2xP to be 1.5 µM and 1.7 µM
respectively. The similar values obtained suggest a relatively high degree of precision
between the two assays. Additionally, this implies that in SPR assays binding of Pin1 to
peptides on the surface of the chip is neither hindered nor enhanced by the chip surface
itself.
Collectively, this data demonstrates the importance of phosphorylation for Pin1
interaction with our CDC25C-derived peptide. A target with two phosphorylation sites is
bound by Pin1 with a relatively high affinity, while a non-phosphorylated target seems to
exhibit no interaction with Pin1. These results are not unexpected, as the binding
determinants of Pin1 (pSer/Thr-Pro) have been described, however, it was imperative to
establish a positive and negative binding result in both assays to facilitate the remainder
of this study. Additionally, these results confirmed the use of our CDC25C peptides
based on the sequence of human protein as a suitable Pin1 target to further assay binding
determinants.
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Figure 11. Fluorescence polarization results indicate that binding of Pin1 to
CDC25C-derived peptide is phosphorylation-dependent, and not a result of nonspecific binding to fluorescein tag.

A. Fluorescence polarization assay for Pin1 binding to 2xP and De-P. Labelled peptide
was incubated with indicated concentrations of full length Pin1 prior to measuring
fluorescence polarization. Each data point represents the mean of 2 (De-P) or 6 (2xP)
independent experiments, with error bars representing the standard deviation.

B. Fluorescence polarization assay for Pin1 binding to fluorescein-5-maneimide tag.
Fluorescein was incubated with indicated concentration of full length Pin1 prior to
measuring fluorescence polarization. Each data point represent the mean of 3 independent
experiments, with error bars representing the standard deviation.
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3.4 Effect of number of phosphorylation sites on Pin1-CDC25C
peptide interaction
With the knowledge that the interaction between Pin1 and its peptide target is
phosphorylation-dependent, and the confirmation that a doubly-phosphorylated peptide
was a suitable binding target, we next sought to determine the effect on binding when
only a single amino acid is phosphorylated.
As previously described, both CDC25C derived peptides containing a single
phosphorylated residue were immobilized onto one flow cell of individual CM5 chips
using the ligand thiol method. Following Pin1 injections, dissociation was monitored.
The SPR results indicated that Pin1 has similar binding to both singly-phosphorylated
peptides (Figure 12A, B). The spike seen in the sensorgram for 1xP #1 (Figure 12A), in
which 14.8 µM Pin1 was injected can be attributed to a bubble present in the system.
Similar spikes in response units were seen elsewhere (see Appendix 6.1).
Although it appears that binding to either single-site phosphorylated peptide is similar to
binding to the doubly-phosphorylated peptide (compare Figure 10B with Figures 12A,
B), close examination of the qualitative characteristics of the sensorgrams highlights
some important differences. With regards to the association phase, the curvature appears
to be greater in Figure 10B than either of Figures 12A or B. Also, Figures 12A and B do
not reach equilibrium, and their dissociation phases appear to be quite pronounced. This
is in contrast with the more apparent equilibrium phase seen in Figure 10, as well as the
more gradual change seen in the dissociation phase which is indicative of a slower release
of analyte. Taken together, these differences make it difficult to generate accurate kinetic
data for the singly-phosphorylated peptides to compare with the dissociation constant
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Figure 12. SPR and fluorescence polarization results indicate that binding of Pin1 is
reduced on a single-site phosphorylated CDC25-derived peptide.

A. and B. Sensorgrams of SPR analyses of the interaction between Pin1 and 1xP #1
peptide (A.), and Pin1 and 1xP #2 peptide (B.). Indicated concentrations of Pin1 were
injected through both flow cells for 1 minute. The curves show the specific signal
obtained after subtraction of background.

C. Fluorescence polarization assay for Pin1 binding to 1xP #1 and 1xP #2.
Independently, labelled peptide was incubated with indicated concentrations of full
length Pin1 prior to measuring fluorescence polarization. Each data point represents the
mean of 3 independent experiments, with error bars representing the standard deviation.
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generated for the doubly-phosphorylated peptide. However, the sensorgrams do suggest
that binding affinity to either of the single-site phosphorylated peptides is decreased in
comparison to the binding to the doubly-phosphorylated peptide.
Binding data from fluorescence polarization between Pin1 and each of the single-site
phosphorylated peptides seemed to suggest a lack of binding to 1xP #1 and 1xP #2
(Figure 12C). The low levels of fluorescence polarization were indicative of a very weak,
or non-specific, interaction between the peptides and Pin1, similar to that which was seen
in the interaction between Pin1 and the fluorescein tag alone (Figure 11B). These results
support our interpretation of SPR results as showing decreased binding between Pin1 and
a single-site phosphorylated target.
The difficulty in interpreting the SPR results obtained here may be attributed to the
limitation of a fixed target in the SPR assays. As the density of immobilized peptide is
difficult to determine, it is conceivable that full length Pin1 is using both domains to bind
to two phosphorylated sites on separate neighbouring peptides at the same time. This
could produce a false or overestimated binding result. Alternatively, it is also possible
that length of the tagged peptide may have affected the results in the fluorescence
polarization assays. Specifically, even if Pin1 bound to the phosphorylated site, the Cterminal tag may still have retained sufficient mobility to prevent polarization of light as
a result of the peptides length. This would have underestimated the binding between Pin1
and the peptide.
In general, however, the results presented thus far appear to suggest that Pin1 binds
preferentially to our doubly phosphorylated peptide (compare Figures 10B and 11A with
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Figure 12).
Given that Pin1 has two binding domains, these results may support a hypothesis that
Pin1 binds CDC25C using both domains simultaneously. To test this hypothesis, and
attempt to clarify the results seen when Pin1 binds to singly phosphorylated targets, we
performed the following experiments.

3.5

Binding of Pin1 to CDC25C peptide requires both domains

Given the differing results generated with regards to Pin1 binding to singlyphosphorylated targets, we chose to address the same question using a different approach.
If Pin1 has the ability to bind to a single phosphorylated site on a target, it may be
binding with only one of its domains. If this were the case, mutants of Pin1 with binding
deficiencies in either the WW or PPIase domains should still maintain the ability to bind
to a phosphorylated target. Therefore, we utilized full-length Pin1 constructs with
mutations in the WW (Y23A) and PPIase domains (R68/69A), which have been shown
previously to have binding deficiencies (12, 28, 71). These proteins were used in SPR
and fluorescence polarization assays with 2xP, identical to those previously described.
We chose to conduct these experiments with the doubly-phosphorylated peptide in case
either of the phosphorylated sites was inadvertently targeted by one domain or the other.
Use of the doubly-phosphorylated peptide allows both sites to be available for binding by
the functional Pin1 domain, and thus ensures that binding is neither over- nor underestimated.
Similar to the results obtained in SPR and fluorescence polarization analyses with regards
to Pin1 and singly-phosphorylated targets, SPR data here indicated that Pin1 mutants
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bind to 2xP, while fluorescence polarization indicates a lack of binding (Figure 13).
Considering the binding deficiencies of each mutant, as a result of a mutant WW (Y23A)
or PPIase domain (R68/69A), it is unlikely that Pin1 binding was being over estimated in
the SPR assay as a result of binding multiple peptides simultaneously. It may be more
likely that binding measured through fluorescence polarization was being underestimated,
as a result of a peptide that was still mobile enough to prevent polarization of light.
Generally speaking, given that there is a close correlation between the SPR response
(measured in RU) and the amount of surface bound protein (76), we can compare the
results generated from the same chip when proteins of the same molecular weight are
used. With regards to the doubly-phosphorylated peptide, binding by wild-type Pin1
resulted in a greater value of RU than did binding by either of the domain mutants,
R68/69A or Y23A (compare Figure 10B with Figure 13A, B). We can therefore infer that
binding by wild-type Pin1 was stronger than either of the domain mutants.
Overall, the results from both SPR and fluorescence polarization appear to suggest that
binding of Pin1 to a doubly-phosphorylated CDC25C-derived peptide was greater when
both Pin1 domains are intact. This would appear to suggest that optimal binding of Pin1
to CDC25C involves both domains.

3.6 Individual Pin1 domains are not sufficient to bind CDC25C
peptide
As a dual-domain isomerase, it has been hypothesized that the WW domain of Pin1 acts
as a protein-targeting domain, while the PPIase domain performs isomerization,
consistent with the sequential model of interaction (11). However, thus far, and consistent
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Figure 13. Binding of Pin1 to CDC25C-derived peptide requires both the WW and
PPIase domains.

A. and B. Sensorgrams of SPR analyses of the interaction between mutant Pin1 (Y23A
(A.) and R68/69A (B.)) and 2xP. Indicated concentrations of mutant Pin1 were injected
through both flow cells for 1 minute. The curves show the specific signal obtained after
subtraction of background.

C. Fluorescence polarization assay for indicated Pin1 mutants binding to 2xP.
Independently, labelled peptide was incubated with indicated concentrations of full
length Pin1mutants prior to measuring fluorescence polarization. Each data point
represents the mean of 3 independent experiments, with error bars representing standard
deviation.
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with previous research (71) our results suggest that for CDC25C the sequential model
does not apply. To further test this, we investigated the binding of individual Pin1
domains with our doubly phosphorylated target. As previously described in section 3.5,
the doubly phosphorylated peptide was chosen to ensure both phosphorylation sites were
available, in case one inadvertently targeted one domain preferentially. The results from
both SPR and fluorescence polarization assays indicated that individual domains of Pin1
were insufficient to bind to our phosphorylated target (Figure 14). This data is in
congruence with data from previous sections, and further supports the hypothesis that
binding of Pin1 to CDC25C requires the presence of both domains.

3.7

Lack of binding is not due to misfolded proteins

To ensure that any lack of protein binding in either SPR or fluorescence polarization
assays was not due to the presence of misfolded proteins, we carried out a series of
additional experiments to ensure that all proteins exhibited normal and expected results.
To test for function in PPIase domain-containing constructs, we carried out in vitro
isomerase assays to ensure that activities were similar to those previously described. A
comparison of the relative activities reported as a percent are displayed in Figure 15. A
catalytic site mutant of Pin1, C113S, shown previously to have minimal (2 % of wild
type) catalytic activity (77) was used as a negative control. Collectively, these results
indicated that the PPIase-containing constructs used in this study retained activity, and
thus were in the correct conformation to bind substrates, as well as our target peptides.
To further investigate the notion that lack of binding may be attributed to misfolded
protein, we employed DSC to perform a controlled heat-denature of full length Pin1.
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Figure 14. Individual Pin1 domains are not sufficient to bind to CDC25C-derived
peptide.

A. and B. Sensorgrams of SPR analyses of the interaction between Pin1domains (PPIase
(A.) and WW (B.)) and 2xP. Indicated concentrations of Pin1 domains were injected
through both flow cells for 1 minute. The traces show the specific signal obtained after
subtraction of background.

C. Fluorescence polarization assay for indicated Pin1 domains binding to 2xP.
Independently, labelled peptide was incubated with indicated concentrations of Pin1
domains prior to measuring fluorescence polarization. Each data point represents the
mean of 2 independent experiments with error bars representing the standard deviation.
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Figure 15. In vitro isomerase activities of PPIase domain-containing constructs used
in this study.

A comparison of the in vitro isomerase activities of all PPIase containing constructs used
in this study. Activities are reported as a percent. Pin1 C113S, a catalytic-site mutant of
Pin1, known to have no isomerase activity, was used as a negative control. Results are
based on the mean of 3 independent experiments, with error bars indicating the standard
deviation.
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Protein unfolding was monitored as a function of heat capacity (Figure 16A), and protein
sample was extracted from the apparatus prior to precipitation and aggregation. This
sample was then immediately used for SPR and fluorescence polarization assays. Results
of these assays (Figure 16B and C) were indicative of a lack of binding.
The WW domain construct of Pin1 presented a different problem with regards to testing
for proper folding, as an in vitro isomerase assay would not be of any use. Instead, we
assayed binding via SPR using our GST-tagged Pin1 WW domain, and upon seeing no
binding (Figure 17A), we then confirmed the binding capacity of the construct by
utilizing it in a GST-pulldown assay (Figure 17B). The binding results were visualized by
blotting with the MPM2 antibody, and showed a characteristic decrease in binding by the
WW domain, but not a lack of binding (71). Additionaly, the blot was also probed using
antibody for p54nrb, a protein which has previously been shown to bind both full-length
Pin1, and the WW domain (71). These binding results indicated that the GST-tagged Pin1
WW domain had the ability to bind targets from a mitotic lysate, however, the same
protein did not bind to our immobilized peptide.
Collectively, these results suggest that a lack of binding seen in SPR and/or fluorescence
polarization assays cannot be attributed to proteins that are misfolded, and lack function.
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Figure 16. Heat-denatured full length Pin1 loses ability to bind CDC25C-derived
peptide.

A. Normalized data for denaturing of full-length Pin1 using DSC. Protein sample was
removed just prior to 60°C, to prevent protein precipitation.

B. Sensorgram of SPR analyses of the interaction between heat-denatured Pin1 and 2xP.
Heat-denatured Pin1 was injected through both flow cells for 1 minute. The trace shows
the specific signal obtained after subtraction of background.

C. Fluorescence polarization assay for heat-denatured Pin1 binding to 2xP. Labelled
peptide was incubated with indicated concentrations of Pin1 prior to measuring
fluorescence polarization Data points represent the mean of 2 independent experiment
with error bars indicating the standard deviation.
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Figure 17. GST-tagged Pin1 WW domain has binding capabilities, but will not bind
in SPR assay.

A. Sensorgram of SPR analyses of the interaction between GST-tagged Pin1 WW
domain and 2xP. Indicated concentration of protein were injected through both flow cells
for 1 minute. The trace shows the specific signal obtained after subtraction of
background.

B. Mitotic HeLa cell lysates were used in GST and GST-Pin1 fusion protein binding
assays. Proteins bound to the GST and GST-Pin1 beads were run on 10% SDS-PAGE
gel and transferred to membranes. Blots were probed with antibody for MPM2 and
NonO.
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4.0

Discussion

The interaction between Pin1 and CDC25C was first identified from a screen of a subset
of many mitotic phosphoproteins (28) and has since been characterized more extensively
(12, 19, 28-30, 65-71). The interest in these two enzymes is no doubt fueled by the
implications of their interaction; Pin1-catalyzed isomerization of CDC25C regulates its
dephosphorylation and thus inhibition, preventing entry into mitosis (28, 30). This was an
important discovery which identified Pin1 as an important mitotic regulator, and provided
evidence of mechanisms for post-phosphorylation regulation. One of the key features in
understanding the interaction between Pin1 and CDC25C stems from the structure of
Pin1 as a dual-domain isomerase; having a WW domain and a PPIase catalytic domain
which can both bind to the pSer/Thr-Pro motif (9, 12), raises the question of how Pin1
uses each domain when binding to, and subsequently catalyzing isomerization of, its
interactors. With regards to CDC25C, the suggestion that full-length Pin1 was required
for the interaction (71) led to the hypothesis that binding was being facilitated by both
domains, simultaneously.

4.1

Pin1 interacts with CDC25C

As a first step towards elucidating the mechanism of binding between Pin1 and CDC25C,
we sought to confirm their known interactions. To this end, and for subsequent assays,
protein purifications were performed and sufficient amounts of GST-tagged and untagged
versions of Pin1 were obtained. Following GST-pulldown assays, and consistent with
previous research (28, 71), we found that CDC25C interacts with Pin1 in a manner that
appears to require the presence of both intact domains. To further investigate both the
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domain and phosphorylation requirements that facilitate this interaction, we choose to
employ a peptide-based strategy, utilizing two independent assays. Such peptide-based
approaches to investigate the interaction between Pin1 and CDC25C (human-, and
Xenopus-derived) are found widely in the literature (12, 19, 67-70). In addition, a
bivalent peptide target has previously been shown to have far greater affinity for Pin1
when compared to a monovalent target (78). However, a study that combines an
investigation of the domain requirements of Pin1 with an analysis of the impact of the
number of phosphorylated binding sites has not been published. As a result, our use of a
multiphosphorylated human CDC25C-derived peptide is unique.

4.2 The interaction between Pin1 and CDC25C peptide is
phosphorylation-dependent
Despite having multiple sites which would, upon phosphorylation, meet the requirements
for the pSer/Thr-Pro Pin1 binding motif, T48 and T67 have been identified as the Pin1
binding sites (12, 30). Our binding results with SPR and fluorescence polarization show
that the interaction between Pin1 and our peptide is phosphorylation-dependent. The loss
of binding to a non-phosphorylated target is comparable to that seen in studies with full
length protein, whereby mutations of T48 and T67 to non-phosphorylatable residues
results in loss (or near loss) of detectable binding (30, 77).
The dissociation constants calculated as a result of our SPR and fluorescence polarization
assays with Pin1 and 2xP are 1.5 µM and 1.7 µM respectively. These values are not
dramatically different from those found by Daum et al. (78) whose bivalent ligands had
dissociation constants of 0.4-0.8 µM when measured with isothermal titration
calorimetry. Perhaps this is an unfair comparison however, given that the peptides used in
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the Daum et al. study (78) were designed to specifically target both the Pin1 WW and
PPIase domains, and thus, bound in a specific orientation. Additionally, those peptides
contained only a single phosphorylated residue, and did not resemble a natural Pin1 target
sequence. It would therefore be expected that such engineered peptides would bind with
somewhat higher affinity than those used in the present study.
Similar to our study, previous work has used multiphosphorylated peptide approaches to
investigate the binding affinity between Pin1 and physiologically relevant targets.
Verdecia et al. (19) used florescence polarization to determine the binding affinity
between Pin1 and a peptide derived from the c-terminal domain of RNA polymerase II (a
known Pin1 interactor). Their peptide sequence, containing two phosphorylation sites,
was significantly shorter than ours, and had phosphorylation sites which were separated
by only two amino acid residues (Table 2). These factors may account for their higher
dissociation constant of 10 µM. A systematic approach to test this hypothesis would be
necessary, as it may be a contributing factor to the differences in binding affinities
between our results and those previously published. An additional point of interest lies in
the fact that the phosphorylated residues in the Verdecia et al. (19) peptides were serine
residues. It has been previously shown that the pSer-Pro motif binds with lower affinity
compared to the pThr-Pro motif, possibly a result of subtle conformational differences
between the two sequences (79, 80). Similarly, Smet et al. (37, 81) characterized the
interaction between Pin1 and multiphosphorylated peptides derived from Tau and also
obtained high dissociation constants. One of their shorter peptides, with 14 residues and
only two amino acids between each of two phosphorylated residues (Table 2) had a high
dissociation constant of 160 µM (81). However, with a much longer
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Table 2. Comparison of peptides used in the literature, with one used in the present
study.

Peptide Sequence

YpSPTpSPS

SRSRpTPpSLPTPPTR

Peptide

Number of

Length

intervening

(number

residues between

of

phosphorylation

residues)

sites

7

2

14

1

Citation

(19)

(81)
GSPGTPGSRSRpTPpSLPTPPTREPKKVAVVRpTPPKSPSSAK

40

1, 16

PDVPRpTPVGKFLGDSANLSILSGGpTPKRSLDWAAAC

36

18

Current
study

71

peptide (comprising 40 residues, 3 of which were phosphorylated) (Table 2) a
dissociation constant of 70 µM was determined. Interestingly, two of the three
phosphorylated residues in this longer peptide were spaced 16 amino acids apart,
suggesting that the greater distance between phosphorylated residues may have
contributed to enhanced binding by Pin1. This hypothesis of cooperativity between
phosphorylated sites leading to enhanced binding has previously been proposed (37, 74),
as a result of the identification of Pin1 interactors with multiple pSer/Thr-Pro sites, which
are often spaced 18-22 amino acids apart. As our peptide meets this criterion, it is
possible that such spacing contributed to our relatively strong binding. Taken together,
the data presented above suggests that the determinants of Pin1 binding lie in optimal
number and positioning of phosphorylated residues. Future work could include sequence
analyses of interactors containing multiple Pin1 binding sites to determine if a pattern of
recognition exists beyond a single pSer/Thr-Pro site, to include both pSer/Thr-Pro sites
and the intervening residues. This knowledge may help identify additional Pin1
interactors, and will likely be valuable for the design of inhibitors of Pin1.

4.3 Effect of number of phosphorylation sites on Pin1-CDC25C
peptide interaction
To further investigate the impact of number of phosphorylation sites on Pin1 binding, we
designed singly-phosphorylated peptide variants of our original peptide, and tested them
for interaction with full length Pin1. Although these peptides appeared to show some
binding when using SPR, these results could not be confirmed using fluorescence
polarization. As discussed previously (section 3.4) there are confounding factors with
both assays which could have contributed to the results obtained, and a systematic
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approach to assessing these factors would be an appropriate next step. This would be of
great significance, given that singly-phosphorylated peptides derived from CDC25C have
been previously shown to have varying binding affinities for Pin1 (19). Of those peptides,
one included the same phosphorylated residue as our 1xP#1 (T48), and had a dissociation
constant of 4.9 µM, measured using fluorescence polarization (19). That peptide,
however, was significantly shorter (six residues) than the ones used in our study. Given
that the WW domain of Pin1 recognizes up to five consecutive residues in a peptide (19),
and that the PPIase domain has been shown to optimally bind peptides that are five
residues in length (10, 82), a short (six residue) peptide would likely bind either the WW
or PPIase domain of Pin1 with relatively high affinity. When used in a fluorescence
polarization assay, this short, tightly bound peptide, would likely retain little mobility,
and polarization of light would be greater. In contrast, if either the WW or PPIase domain
of Pin1 were to bind to the single phosphorylated residue on 1xP #1 or 1xP #2, including
two residues on either side, it may not stabilize the remainder of the peptide sufficiently
to cause polarization of light. This may have contributed to the apparent low binding we
saw with Pin1 and either of the singly phosphorylated peptides when assaying
fluorescence polarization.
Collectively, our data show that singly-phosphorylated targets appear to bind with lower
affinity than our doubly-phosphorylated peptide. This finding is consistent with previous
research conducted with peptides derived from other Pin1 interactors. Results using
peptides derived from the c-terminal domain of RNA polymerase II show that a doublyphosphorylated peptide has the greatest binding affinity when compared to singlyphosphorylated versions (19). Similarly, using Tau-derived peptides, Smet et al. (37, 81)
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found that a second phosphorylated residue increased the affinity of Pin1 for the peptide.
Interestingly, they also found that the additional phosphate also decreased the isomerase
activity of Pin1 (81). It would be interesting to test the impact of the second
phosphorylated residue using our CDC25C-derived peptides, to determine if the
inhibitory effect seen with Tau applies to other Pin1 substrates as well.

4.4

Binding of Pin1 to CDC25C targets requires both domains

Given the somewhat inconclusive results obtained with Pin1 and the singlyphosphorylated peptides, we next chose to investigate the possibility of single-domain
binding from an alternative perspective, using binding-deficient domain-mutants of Pin1.
We hypothesized that binding of wild-type Pin1 to singly-phosphorylated targets should
be able to be replicated using domain-mutants of Pin1, given that binding to a singlyphosphorylated peptide may be occurring using a single domain only. To this end, we
used binding-deficient mutants of Pin1, with Y23A and R68/69A mutations in the WW
and PPIase domain respectively, and measured their binding to the doubly
phosphorylated peptide. Similar to the data we presented in section 3.4, we observed a
discrepancy in the results between SPR and fluorescence polarization. While results from
SPR suggest that both domain mutants bind the peptide, albeit with lower affinity than
wild-type, fluorescence polarization data indicates a weak, possibly non-specific,
interaction. Given that the mutants would likely be binding the doubly-phosphorylated
peptide at only one site, we hypothesize that this may be insufficient to reduce the
mobility of the lengthy peptide, and therefore polarization of light would not occur.
Overall, although there are unresolved discrepancies between our data generated with
SPR and fluorescence polarization, it seems that full length Pin1 has the greatest binding
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affinity when both domains are intact, and when the target peptide sequence is doublyphosphorylated.

4.5 Individual Pin1 domains are not sufficient to bind to
CDC25C target peptide
Our final step in assaying the interactions between Pin1 and our CDC25C-derived
peptide was to test the binding ability of the individual domains of Pin1. The results we
obtained indicate a lack of binding between either of the domains and the doublyphosphorylated peptide. This supports our hypothesis that both intact domains are
required for binding. However, previous studies have shown that both domains of Pin1
have the ability to bind to target peptides with varying affinities. More specifically,
although structures determined using x-ray crystallography have been solved with
peptides bound to the PPIase domain of Pin1 (9, 10), a peptide-based binding analysis
similar to ours determined that the PPIase domain exhibited no detectable binding to
multiple peptides (19). The few peptides which did bind the PPIase domain exhibited
binding affinities in the range of 85 to over 500 µM (19). These results, indicating
relatively poor binding by the PPIase domain, are consistent with ours, and are also in
agreement with in vitro studies which show that the PPIase domain of Pin1 is not able to
bind phosphoproteins (12, 71). The catalytic function of the PPIase domain suggests that
it must have some binding affinity towards substrates, however, it appears to be difficult
to measure these interactions. This may be a result of substrates having only transient
interactions with this domain (82), given the active site appears to be “primed” for
catalysis, even without bound substrate (83). With regards to the WW domain of Pin1,
peptides derived from various known Pin1 interactors have been shown to bind with
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dissociation constants ranging from 2 to 125 µM (12, 19, 67, 68). The relatively large
range of dissociation constants (similar to those obtained for interactions with the PPIase
domain) suggests that binding affinities are dependent upon both peptide sequence and
length (both of which varied in the sampled studies), and overall, that in some cases
individual domains may not be sufficient for binding. Innes et al. (71) presented data to
suggest that the domain requirements for binding differ depending on the interactor; some
interactors (for example, RNA binding protein p54nrb) require only the WW domain,
while others (for example, protein kinase PLK1), appear to require both domains of Pin1.
There have been multiple other interactors which have been shown to require both
domains of Pin1 for interaction and subsequent function, including the transcription
factor c-Jun (24), tumor suppressor protein p53 (34), transcription activator β-catenin
(25), and protein kinase CK2 (73). Collectively, our results suggest that CDC25C is
another protein which requires, and binds optimally to, both domains of Pin1.

4.6

Lack of binding is not due to misfolded proteins

Given the somewhat contradictory results we generated, we sought to ensure that the
proteins we used in SPR and fluorescence polarization assays were functional in
alternative assays. Constructs containing the PPIase domain were assessed based on their
isomerase activity, and were found to have activities within the range of data previously
published (12, 15, 77). If our constructs were in the correct conformation to bind and
isomerize a substrate in an in vitro isomerisation assay, we conclude that they must also
be in the correct conformation to facilitate binding to our peptides. As a result, we
conclude that any lack of binding by any of our constructs is not due to a misfolded
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protein. To further this point, our heat-denatured Pin1 showed no binding in either SPR
or fluorescence polarization assays.
Without an activity assay to test the function of the Pin1 WW domain, we chose to test its
binding capacity as a fusion construct with GST. Our GST-WW domain had the ability to
bind varying interacting partners in a GST pulldown assay, similar to those previously
published (12, 71). However, the same GST fusion construct failed to bind our peptide
via SPR. We propose that this difference in binding capacity is a result of our specific
CDC25C-derived peptide; as explained in section 4.5, binding appears to require the
presence of both domains of Pin1.
Overall, the results of these assays demonstrate that our proteins retain function in
various alternative assays, and a lack of binding to our peptides is not a result of a
misfolded construct.

4.7

Model of Pin1 binding to CDC25C

As reviewed in Section 1.6, there are multiple models to describe the interactions
between Pin1 and its binding partners. Given the results presented here, that interactions
between Pin1 and CDC25C appear to require the presence of both, intact domains, we
suggest that neither the multimeric nor catalysis-first models adequately fit the data.
Additionally, given that the individual domains of Pin1 lack the ability to bind both our
CDC25C-derived peptides and full-length CDC25C (71), we propose that the sequential
binding model is similarly a poor fit, as this model would require initial targeting by the
WW domain. As a result, the simultaneous binding model appears to be best suited to
explain the interactions seen. As previously discussed, this model suggests that although

77

individually, two pSer/Thr-Pro sites may be poor binding sites for either domain of Pin1,
the simultaneous binding of both sites by both domains results in a higher affinity
interaction (71). As reviewed in Section 4.3 there are additional examples to demonstrate
that binding affinity is increased with a doubly-phosphorylated peptide. These example
peptides may or may not be interacting with Pin1 in a simultaneous manner, and an
examination of the affinity each has with the WW and PPIase domains would help to
determine this. However, given that our results show relatively weak affinity for each of
the singly-phosphorylated peptides, yet relatively high affinity with the doublyphosphorylated peptide, it appears that interactions with CDC25C are occurring in a
simultaneous manner. These results support the suggestion made by Innes et al. (71) that
CDC25C is an interactor that binds according to the simultaneous model.
Considering that there is evidence that Pin1 may not interact with all its binding partners
in the same way, or by the same model (71), a next step would be to investigate what
determines and/or regulates these differences. Although it is beyond the scope of this
work to speculate on the specifics of this, previous work by Jacobs et al. (72) showed that
interactions between the domains of Pin1 changed depending on the sequence of the
bound peptide. These inter-domain interactions may serve to coordinate binding of
multiple sites simultaneously, which would otherwise not be bound with high affinity.
Additionally, as there may be sequence determinants that facilitate each model of
binding, a thorough investigation to compare interactors would be appropriate.

4.8

Future directions

As noted previously, there are still outstanding issues to address, as well as additional
experiments that can further the present study. Firstly, with regards to our suggestion that
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the length of our peptides could have been a confounding factor in our fluorescence
polarization assays, shorter peptides should be used in additional experiments. These
shorter peptides may have less mobility once bound by Pin1, and as such, may provide a
more accurate representation of binding.
Given the suggestion that peptide length, as well as the number of residues between the
phosphorylation sites, may have contributed to differences between our data and those
previously published, an investigation into how these factors contribute to binding by
Pin1 would be of interest. To this end, a sequence analysis of residues between binding
sites may reveal a pattern of residues, or an optimal length, both of which may help to
further classify Pin1 interactors based on the modes of binding.
To confirm the data generated in this study, additional assays using our peptides could be
performed. Isothermal titration calorimetry may provide more precise binding data, and
thus resolve some of the discrepancies with the current data. In addition, sedimentation
equilibrium assays would ensure that interactions between Pin1 and our peptides were
occurring in a 1:1 ratio.
Finally, as mentioned previously, CDC25C is one of multiple Pin1 interacting proteins
that have more than one identified Pin1 binding site, and these additional interactors may
bind to Pin1 in a similar fashion to CDC25C, using the simultaneous model. One such
protein of interest is the microtubule binding protein Tau. The interaction between Pin1
and Tau has already been a subject of research (30, 36, 37, 81, 84), given the implications
their interaction has with regards to contributing to Alzheimer’s disease. Similar to
CDC25C, Tau has two identified Pin1 binding sites, which are separated by nineteen
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amino acids (T212 and T231) (36, 37), and based on the similarities between previous
Tau peptide work discussed in sections 4.2 and 4.3 and our own data, it may be possible
that Tau is another interactor to which Pin1 binds via the simultaneous model. As peptide
studies have already been performed, in vitro studies would be a next step to confirm the
interaction seen. To this end, we performed preliminary GST-pulldown experiments to
test the interactions between full-length Pin1 and Tau. These experiments and their
results are presented in Appendix 1. Although these pulldown results should be
confirmed with additional assays, it appears that the binding requirements of Tau are
similar to those of CDC25C. Taken together with previously published Tau-derived
peptide studies, the data suggest that Tau may another interactor to which Pin1 binds via
the simultaneous model.

4.9

General summary

The objective of this study was to elucidate the mechanism with which Pin1 interacts
with a key mitotic trigger, CDC25C. Despite the caveat that our results display some
discrepancies, some important conclusions can still be made. Firstly, the binding of Pin1
to our peptides was phosphorylation-dependent. Additionally, Pin1 bound to a doublyphosphorylated peptide with higher affinity than either of the singly-phosphorylated
peptides. This result suggested that binding to our doubly-phosphorylated peptide was
facilitated using both domains of Pin1 simultaneously, each binding a single
phosphorylation site. An investigation to determine the binding ability of the individual
domains resulted in lack of binding. Furthermore, mutant versions of Pin1 with domainspecific binding deficiencies bound with lower affinity than wild-type Pin1. These results
provide additional evidence that interactions with human CDC25C appears to require
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both, intact domains of Pin1. Finally, to ensure that our binding results were not being
affected by misfolded proteins, additional assays were performed, and ensured all
proteins were functional in other (binding-dependent) capacities. Collectively, these
results are consistent with the simultaneous model of binding, in which Pin1 binds
CDC25C with both domains at the same time.
The existence of multiple models describing the interaction between Pin1 and its targets
is perhaps not surprising given the structure of Pin1 as a dual-domain binding protein.
And although our results suggest that Pin1 binds CDC25C via the simultaneous model,
evidence in support of other models still exists. It is becoming more evident that Pin1
interacts with different proteins in different ways. This dynamic nature of Pin1 is
intriguing from many perspectives, and will likely serve to guide further work with
respect to the structure and function and Pin1, and its potential as a therapeutic target.
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Appendices
Appendix A. Spikes in sensorgrams are relatively common, and
can be attributed to bubbles
The sensitivity of the Biacore instrument makes it susceptible to even the smallest of
impurities in buffer and sample solutions. As a result, filtering and de-gassing of all
buffer solutions is necessary. However, the introduction of bubbles during the injection
process can still occur. Bubbles in the system display as large spikes in the resulting
sensorgram as shown in Figure A1.
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Figure A1. Spikes in SPR sensorgrams can be attributed to bubbles in the system.

A. B. and C. Sensorgrams of SPR analyses showing spikes in responses, attributed to the
presence of bubbles in the system.
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Appendix B. Preliminary data to characterize interactions between
Pin1 and Tau
As previously discussed, we chose to begin investigating the interaction between Pin1
and Tau. Given the similarities between our peptide work and those previously published
using peptides derived from Tau (34, 78), we hypothesized that Tau could be another
interactor to which Pin1 binds via the simultaneous model.
Tau is endogenously expressed in multiple isoforms, which differ in length as a result of
the presence or absence of (sometimes multiple) binding domains (see Figure A2A). In
addition to the two identified Pin1 binding sites, Tau contains 13 sites which, when
phosphorylated, match the Pin1 binding sequence, pSer/Thr-Pro (Figure A2B). Some of
these sites are located within the repeated domains of Tau, and as a result, we chose to
use a long isoform of Tau, 2N4R, so as not to preclude binding by Pin1 to other sites.
To investigate the interaction, we performed GST pulldowns (as previously described)
using mitotic HeLa cell lysates. Cells had been transiently transfected with wild-type
EGFP-Tau, or either single or double phosphorylation site mutants (T212A, T231A, or
T212/231A respectively). Proteins that bound to GST or GST-Pin1 fusion proteins were
examined by immunoblotting with GFP antibody. The results shown in Figure A3
demonstrate that Tau follows the same pattern of binding to Pin1 as endogenous
CDC25C, with the R68/69A mutant of Pin1 showing a decreased interaction. Mutations
of either of the Pin1 binding sites resulted in significantly decreased binding, as did the
double mutant.
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These results are similar to those seen for CDC25C (compare Figure A3 with Figure 7),
suggesting that Tau may be another interactor of Pin1 which binds via the simultaneous
model.
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Figure A2. Illustration of Tau isoform used in this study.

A. Representation of Tau isoform 2N4R used in this study. This isoform of Tau is a 441
amino acid protein, consisting of 2 repeats of the N domain, and 4 repeats of the R
domain. The approximate locations of identified Pin1 binding sites are shown.

B. Human Tau isoform 2N4R protein sequence is shown, with identified Pin1 binding
sites shown in bold with underlining. Additional sites which could (upon
phosphorylation) meet Pin1 binding requirements are shown in bold only. Amino acid
numbers are indicated on the left. (UniProt P10636-8)
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Figure A3. GST-pulldowns with wild-type and phosphorylation site mutants of Tau
2N4R

A. Mitotic HeLa cell lysates were used in GST-Pin1 fusion protein binding assays. Cells
were transfected with EGFP-Tau constructs, expressing wild-type Tau (isoform 2N4R) or
phosphorylation site mutants, T212A, T231A, or T212/231A. Proteins bound to the GSTPin1 beads were run on 10% SDS-PAGE gel and transferred to membranes. Blots were
probed with antibody for EGFP.

B. Quantification of blots shown in figure A. Results are the mean of 3 independent
pulldown experiments, with error bars indicating the standard deviation.
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Appendix C. Permissions to use copyrighted material (Springer
Science+Business Media)
Portions of this thesis have been previously published (85), and are used in this current
work with kind permission of Springer Science+Business Media. Liscences for use of
text and figures are included on the following pages.
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